Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) shares hit a new 52-week low on Monday . The stock traded as low as $51.00 and last traded at $51.00, with a volume of 10 shares trading hands. The stock had previously closed at $54.00.
Basilea Pharmaceutica Stock Down 5.6 %
The company has a debt-to-equity ratio of 5.70, a current ratio of 4.10 and a quick ratio of 3.27. The stock’s 50 day simple moving average is $53.23 and its 200-day simple moving average is $52.86.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
- Short Selling – The Pros and Cons
- Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Hot New IPOs Defying the 2025 Market Slump
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
